Germany
· Delayed Price · Currency is EUR Innate Pharma Company Description
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally.
The company’s products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.
Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET.
The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited.
Innate Pharma S.A. was incorporated in 1999 and is based in Marseille, France.
| Country | France |
| Founded | 1999 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 181 |
| CEO | Jonathan Dickinson |
Contact Details
Address: 117, Avenue de Luminy Marseille, 13009 France | |
| Phone | 33 4 30 30 30 30 |
| Website | innate-pharma.com |
Stock Details
| Ticker Symbol | IDD |
| Exchange | Frankfurt Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Jonathan Dickinson | Chief Executive Officer |
| Frederic Lombard | Chief Financial Officer |
| Yannis Morel | Chief Operating Officer |
| Stephanie Cornen | Head of Investor Relations |